Please Wait...
Robert Scarimbolo is the Manager of Molecular Imaging at BioClinica. He is responsible for developing processes to support and manage molecular imaging projects, including training paradigms and image analysis software validation. He began his career at BioClinica (formerly CoreLab Partners) in 2007 as a Clinical Project Coordinator and has held numerous roles of increasing responsibility within the Global Clinical Operations department. Robert earned his BSc in Health Sciences from Stony Brook University in New York.
Van Heertum RL, Scarimbolo R, Ford R, Berdougo E, O’Neal M. Companion diagnostics and molecular imaging-enhanced approaches for oncology clinical trials. Drug Design, Development and Therapy 2015:9 5215–5223.
Clinicians need ways to better predict patient responses
The estimated cost for developing a drug is approaching upwards of $5 Billion dollars with a process spanning well over a decade. Coupled with high failure rates in late phase clinical trials and increased complexities in acquiring and analyzing clinical trial data, traditional approaches based on the premise of "one size fits all" are becoming less cost effective and suboptimal.
Successful clinical trials require the ability to see key details and uncover hidden insights. Bioclinica utilizes science and technology to bring clarity to clinical trials, helping companies to develop new life-improving therapies more efficiently and safely.
Quick Links:
Language:
